Eli Lilly and Company (LLY) said patients have been dosed in a Phase 1 study of LY-CoV555, the lead antibody from the company's collaboration with AbCellera, in COVID-19 treatment. The patients were dosed at major medical centers in the U.S. under a randomized, placebo-controlled, double-blind trial.
from RTT - Biotech https://ift.tt/2AuUily
via IFTTT
No comments:
Post a Comment